Intellectual Property Enforcement Guidelines

Running head: INTELLECTUAL PROPERTIES AND BARRIERS TO ENTRY
Intellectual Property and Barriers to Entry: Amgen Inc.
Name of the Student
Name of the University
Author’s Note:

1
INTELLECTUAL PROPERTIES AND BARRIERS TO ENTRY
1. Evaluation of Intellectual Property Position of Amgen Inc.
Amgen Inc. is a multinational biopharmaceutical organization in America that provides
various products of biotechnology. They have been doing business for several years and have
been providing health care business on the basis of recombinant DNA technologies. Apart from
providing major advantages to the customers, they are also focusing on their maintenance of
intellectual properties (Amgen Inc. 2020). Since, they are dealing with biotechnology products,
they have involved patents as the main intellectual property in their business. Being the patent
owner, Amgen Inc. has got the exclusive right for preventing as well as stopping others from
commercial exploitation of the patented inventions (Drahos, 2016).
The Chairman, Robert Bradway has ensured that the chief products like Aimovig,
Parsabiv, Repatha, Epogen, Xgeva, Vectibix and many more are patented and could not be used
by any other organization under any circumstance. As a result, the position of intellectual
property of Amgen Inc. is extremely high as compared to other American biotechnology
companies (Sherwood, 2019). Moreover, they are also recruiting jobs for intellectual property in
the company with better experience in work.
2. Evaluation of Barriers to Entry of Amgen Inc.
Barriers to entry refers to the existence of the higher startup costs or any other obstacle,
which can prevent the new competitors from easily getting into the industry or business area
(Ncube et al., 2016). Amgen Inc., being the leading biotechnology company in the US market,
does not face high competition from the new competitors. According to a new act, there is a high
complexity of biologics required new guidelines to demonstrate efficacy and safety for the
biosimilar products from same organization (Biosimilars. 2018). The first entrant was being